Results of GRAIL's Galleri(R) Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology.

GRAIL, Inc. has published detailed findings of its Galleri multi-cancer early detection (MCED) test in prostate cancer in JCO Precision Oncology. The data from the study support the clinical performance of the Galleri test in screening for aggressive prostate cancer while minimizing the risk of overdiagnosis of slow-growing cancers. The analysis showed that the MCED test detected mostly clinically significant prostate cancers, with high accuracy in predicting the cancer signal origin. These findings suggest that the Galleri test can be a valuable tool in detecting biologically significant prostate cancers without contributing to the burden of overdiagnosis. [Extracted from the article]